piracetam has been researched along with Unverricht-Lundborg Syndrome in 7 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Unverricht-Lundborg Syndrome: An autosomal recessive condition characterized by recurrent myoclonic and generalized seizures, ATAXIA, slowly progressive intellectual deterioration, DYSARTHRIA, and intention tremor. Myoclonic seizures are severe and continuous, and tend to be triggered by movement, stress, and sensory stimuli. The age of onset is between 8 and 13 years, and the condition is relatively frequent in the Baltic region, especially Finland. (From Menkes, Textbook of Child Neurology, 5th ed, pp109-110)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disabling myoclonus is the main symptom in long-standing Unverricht-Lundborg disease (ULD), and levetiracetam (LEV) appears to be an effective anticonvulsant with promising short-term antimyoclonic properties." | 2.71 | Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. ( Gelisse, P; Genton, P; Magaudda, A, 2004) |
| "Levetiracetam appears to be a useful antimyoclonic agent in cases of progressive myoclonic epilepsy and should be considered for adjunctive therapy." | 1.34 | Levetiracetam in three cases of progressive myoclonus epilepsy. ( Kkolou, E; Papacostas, S; Papathanasiou, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Kälviäinen, R | 2 |
| Genton, P | 3 |
| Andermann, E | 1 |
| Andermann, F | 1 |
| Magaudda, A | 2 |
| Frucht, SJ | 1 |
| Schlit, AF | 1 |
| Gerard, D | 1 |
| de la Loge, C | 1 |
| von Rosenstiel, P | 1 |
| Crest, C | 1 |
| Dupont, S | 1 |
| Leguern, E | 1 |
| Adam, C | 1 |
| Baulac, M | 1 |
| Gelisse, P | 2 |
| Papacostas, S | 1 |
| Kkolou, E | 1 |
| Papathanasiou, E | 1 |
| Khyuppenen, J | 1 |
| Koskenkorva, P | 1 |
| Eriksson, K | 1 |
| Vanninen, R | 1 |
| Mervaala, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht[NCT00357669] | Phase 3 | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht[NCT00368251] | Phase 3 | 56 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 17.45 |
| Brivaracetam 5 mg/Day | -4.60 |
| Brivaracetam 150 mg/Day | 12.34 |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 0.00 |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -9.68 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 5.41 |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 43.44 |
| Brivaracetam 150 mg/Day | 0.00 |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Brivaracetam 150 mg/Day | 11.1 | 11.1 | 33.3 | 33.3 | 5.6 | 5.6 | 0 |
| Brivaracetam 5 mg/Day | 10.0 | 0 | 30.0 | 50.0 | 10.0 | 0 | 0 |
| Placebo | 0 | 11.1 | 33.3 | 50.0 | 0 | 0 | 5.6 |
1 review available for piracetam and Unverricht-Lundborg Syndrome
| Article | Year |
|---|---|
Clinical picture of EPM1-Unverricht-Lundborg disease.
Topics: Adolescent; Adult; Age of Onset; Animals; Anticonvulsants; Clonazepam; Cystatin B; Cystatins; Diagno | 2008 |
2 trials available for piracetam and Unverricht-Lundborg Syndrome
| Article | Year |
|---|---|
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Drug Therapy, Combination; Female; Humans; Levetir | 2004 |
4 other studies available for piracetam and Unverricht-Lundborg Syndrome
| Article | Year |
|---|---|
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.
Topics: Activities of Daily Living; Adolescent; Anticonvulsants; Child; Drug Evaluation; Drug Therapy, Combi | 2004 |
Levetiracetam in three cases of progressive myoclonus epilepsy.
Topics: Activities of Daily Living; Adult; Anticonvulsants; Drug Therapy, Combination; Female; Humans; Levet | 2007 |
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Encephalitis; Epilepsies, Myoclonic; Humans; Hypo | 2001 |